Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

2021/02/01 by Denis Y. Logunov, Denis Y Logunov, Inna V Dolzhikova +57 · 8 citations
Biochemistry, Genetics and Molecular Biology · Medicine · #SARS-CoV-2 and COVID-19 Research #Virus-based gene therapy research #vaccines and immunoinformatics approaches

paper · pdf · doi:10.1016/s0140-6736(21)00234-8

crossref issued 2021/02/01 · crossref published 2021/02/01 · crossref published-print 2021/02/01 · openalex publication_date 2021/02/01 · crossref created 2021/02/02 · crossref deposited 2025/09/26 · openalex created_date 2025/10/10 · crossref indexed 2026/07/20 · openalex updated_date 2026/07/28

Cited by

• Micro and nanotechnologies: The little formulations that could
• Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
• Mechanisms of SARS-CoV-2 entry into cells
• Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccines
• Narrative Messages, Information Seeking and COVID-19 Vaccine Intention: The Moderating Role of Perceived Behavioral Control
• COVID-19 vaccine efficacy and effectiveness—the elephant (not) in the room
• Das Weltsystem der Impfstoffnutzung
• COVID-19 vaccine acceptance and hesitancy in low- and middle-income countries